Revenue Beat: Blue Jet Healthcare Limited Exceeded Revenue Forecasts By 7.0% And Analysts Are Updating Their Estimates

Blue Jet Healthcare Limited (NSE:BLUEJET) just released its annual report and things are looking bullish. The company beat expectations with revenues of ₹11b arriving 7.0% ahead of forecasts. Statutory earnings per share (EPS) were ₹17.59, 5.3% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Blue Jet Healthcare after the latest results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

After the latest results, the seven analysts covering Blue Jet Healthcare are now predicting revenues of ₹13.2b in 2026. If met, this would reflect a major 23% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 19% to ₹20.98. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹12.9b and earnings per share (EPS) of ₹19.22 in 2026. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.

See our latest analysis for Blue Jet Healthcare

It will come as no surprise to learn that the analysts have increased their price target for Blue Jet Healthcare 6.0% to ₹908on the back of these upgrades. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Blue Jet Healthcare, with the most bullish analyst valuing it at ₹1,150 and the most bearish at ₹730 per share. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Blue Jet Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 23% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 10% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 10% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Blue Jet Healthcare is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Blue Jet Healthcare following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Blue Jet Healthcare analysts - going out to 2028, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 2 warning signs for Blue Jet Healthcare (1 can't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.